Clinical trial
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
NCT00367016 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00367016 |
|---|---|
| Title | Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) |
| Official title | Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) |
| Acronym | Xolair |
| Lead sponsor | University of California, Davis, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Asthma, Allergic Rhinitis, Atopic Dermatitis |
| Intervention type | Drug |
| Interventions | Omalizumab, Placebo |
| Enrollment | 6 |
| Start date | Feb 1, 2004 |
| Primary completion | Oct 17, 2012 |
| Completion | Oct 17, 2012 |
| First posted | Aug 22, 2006 |
| Last update posted | Jul 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: